Lisanti Capital Growth LLC Purchases Shares of 30,410 Krystal Biotech, Inc. (NASDAQ:KRYS)

Lisanti Capital Growth LLC bought a new stake in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 30,410 shares of the company's stock, valued at approximately $5,483,000. Krystal Biotech makes up about 1.6% of Lisanti Capital Growth LLC's investment portfolio, making the stock its 14th biggest position. Lisanti Capital Growth LLC owned about 0.11% of Krystal Biotech as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of the stock. Fifth Third Bancorp increased its holdings in shares of Krystal Biotech by 159.1% in the 1st quarter. Fifth Third Bancorp now owns 171 shares of the company's stock worth $31,000 after buying an additional 105 shares during the last quarter. GF Fund Management CO. LTD. purchased a new position in Krystal Biotech in the fourth quarter worth $95,000. Covestor Ltd increased its stake in Krystal Biotech by 972.7% in the fourth quarter. Covestor Ltd now owns 708 shares of the company's stock valued at $111,000 after acquiring an additional 642 shares during the last quarter. GAMMA Investing LLC increased its stake in Krystal Biotech by 179.3% in the first quarter. GAMMA Investing LLC now owns 673 shares of the company's stock valued at $121,000 after acquiring an additional 432 shares during the last quarter. Finally, US Bancorp DE raised its position in Krystal Biotech by 8.7% during the fourth quarter. US Bancorp DE now owns 1,027 shares of the company's stock valued at $161,000 after purchasing an additional 82 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

KRYS has been the subject of a number of research reports. Chardan Capital reiterated a "buy" rating and issued a $219.00 price objective on shares of Krystal Biotech in a report on Wednesday, May 7th. HC Wainwright reaffirmed a "buy" rating and issued a $240.00 target price on shares of Krystal Biotech in a research note on Tuesday, June 24th. Guggenheim reduced their price target on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Jefferies Financial Group began coverage on shares of Krystal Biotech in a report on Wednesday, March 5th. They issued a "buy" rating and a $245.00 price objective for the company. Finally, Citigroup cut their price objective on shares of Krystal Biotech from $215.00 to $155.00 and set a "neutral" rating for the company in a research note on Friday, May 16th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $211.13.

Krystal Biotech Stock Performance

KRYS traded up $2.34 on Wednesday, hitting $141.35. 209,859 shares of the company were exchanged, compared to its average volume of 287,116. The firm has a fifty day simple moving average of $139.58 and a two-hundred day simple moving average of $157.23. The stock has a market capitalization of $4.09 billion, a PE ratio of 33.98 and a beta of 0.67. Krystal Biotech, Inc. has a 12 month low of $122.80 and a 12 month high of $219.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported $1.20 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.38 by ($0.18). Krystal Biotech had a return on equity of 14.64% and a net margin of 37.17%. The firm had revenue of $88.18 million during the quarter, compared to the consensus estimate of $98.66 million. On average, equities analysts expect that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).